Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 18-Nov-24 4:05 PM View:  | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | BioSante Pharmaceuticals, I... (ANIP) | 15-Nov-24 | Payment of Exercise | 867 | $56.58 | $49,054.90 | (3%) 34.04K to 33.17K | |
| 18-Nov-24 4:03 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 15-Nov-24 | Private Sale | 6,500 | $57.70 | $375,050.00 | (8%) 83.28K to 76.78K | |
| 14-Nov-24 4:16 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 13-Nov-24 | Private Sale (Planned) | 250 | $61.36 | $15,340.00 | (< 1%) 56.49K to 56.24K | |
| 15-Oct-24 5:57 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 14-Oct-24 | Private Sale (Planned) | 250 | $57.19 | $14,297.50 | (< 1%) 56.74K to 56.49K | |
| 16-Sep-24 4:50 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 13-Sep-24 | Private Sale (Planned) | 250 | $56.82 | $14,205.00 | (< 1%) 56.99K to 56.74K | |
| 13-Sep-24 4:23 PM View: | Davis Krista SVP, CHIEF HR OFFICER | BioSante Pharmaceuticals, I... (ANIP) | 12-Sep-24 | Payment of Exercise | 1,486 | $56.15 | $83,438.90 | (3%) 51.55K to 50.06K | |
| 10-Sep-24 4:44 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 08-Sep-24 | Payment of Exercise | 3,646 | $60.51 | $220,619.00 | (< 1%) 377.5K to 373.86K | |
| 14-Aug-24 8:29 AM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 13-Aug-24 | Private Sale (Planned) | 250 | $59.62 | $14,905.00 | (< 1%) 57.24K to 56.99K | |
| 19-Jul-24 5:27 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 18-Jul-24 | Payment of Exercise | 1,743 | $61.35 | $106,933.00 | (3%) 58.98K to 57.24K | |
| 19-Jul-24 5:30 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 18-Jul-24 | Private Sale (Planned) | 2,743 | $62.00 | $170,066.00 | (< 1%) 709.01K to 706.27K | |
| 17-Jul-24 7:07 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 17-Jul-24 | Sale (Planned) | 14,257 | $63.16 | $900,472.00 | (2%) 723.27K to 709.01K | |
| 17-Jul-24 7:07 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 16-Jul-24 | Sale (Planned) | 22,000 | $64.27 | $1,413,940.00 | (3%) 745.27K to 723.27K | |
| 17-Jul-24 7:07 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 15-Jul-24 | Private Sale (Planned) | 11,000 | $63.38 | $697,180.00 | (1%) 756.27K to 745.27K | |
| 15-Jul-24 4:38 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 12-Jul-24 | Private Sale (Planned) | 250 | $64.91 | $16,227.50 | (< 1%) 59.23K to 58.98K | |
| 02-Jul-24 8:58 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 01-Jul-24 | Private Sale (Planned) | 20,000 | $63.44 | $1,268,800.00 | (8%) 262.9K to 242.91K | |
| 24-Jun-24 4:12 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 21-Jun-24 | Private Sale (Planned) | 20,000 | $58.90 | $1,178,000.00 | (3%) 776.27K to 756.27K | |
| 20-Jun-24 7:11 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 20-Jun-24 | Sale (Planned) | 11,447 | $59.86 | $685,217.00 | (1%) 787.72K to 776.27K | |
| 20-Jun-24 7:11 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 18-Jun-24 | Sale (Planned) | 10,607 | $60.76 | $644,481.00 | (1%) 798.33K to 787.72K | |
| 20-Jun-24 7:11 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 17-Jun-24 | Private Sale (Planned) | 7,946 | $61.41 | $487,964.00 | (< 1%) 806.27K to 798.33K | |
| 14-Jun-24 5:23 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 13-Jun-24 | Private Sale (Planned) | 250 | $63.80 | $15,950.00 | (< 1%) 59.48K to 59.23K | |
| 11-Jun-24 4:51 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 07-Jun-24 | Option Exercise | 12,550 | $52.70 | $661,366.00 | 11% 116.37K to 128.92K | |
| 11-Jun-24 4:51 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 07-Jun-24 | Payment of Exercise | 11,087 | $67.70 | $750,590.00 | (9%) 128.92K to 117.83K | |
| 06-Jun-24 6:21 PM View: | Gutwerg Ori SVP, GENERICS | BioSante Pharmaceuticals, I... (ANIP) | 05-Jun-24 | Private Sale | 2,985 | $67.00 | $199,995.00 | (4%) 80.21K to 77.23K | |
| 06-Jun-24 7:34 AM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 04-Jun-24 | Private Sale | 5,000 | $63.58 | $317,900.00 | (3%) 166.97K to 161.97K | |
| 04-Jun-24 6:08 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 03-Jun-24 | Private Sale (Planned) | 20,000 | $64.41 | $1,288,200.00 | (7%) 282.9K to 262.9K | |
| 23-May-24 10:00 PM View: | Walsh Patrick D Director | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Grant | 4,410 | -- | -- | 6% 70.3K to 74.71K | |
| 23-May-24 10:00 PM View: | Pera Antonio R Director | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Grant | 4,410 | -- | -- | 17% 26.63K to 31.04K | |
| 22-May-24 6:14 PM View: | Mutz Christopher HEAD OF RARE DISEASE | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Private Sale | 2,000 | $61.61 | $123,220.00 | (2%) 85.28K to 83.28K | |
| 23-May-24 10:00 PM View: | Thoma Jeanne Director | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Grant | 4,410 | -- | -- | 12% 36.2K to 40.61K | |
| 23-May-24 10:00 PM View: | Haughey Thomas Director | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Grant | 4,410 | -- | -- | 9% 47.12K to 51.53K | |
| 23-May-24 10:00 PM View: | Tannenbaum Renee P Director | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Grant | 4,410 | -- | -- | 24% 18.21K to 22.62K | |
| 23-May-24 10:00 PM View: | Leonard Matthew J Director | BioSante Pharmaceuticals, I... (ANIP) | 21-May-24 | Grant | 4,410 | -- | -- | 58% 7.58K to 11.99K | |
| 21-May-24 5:21 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 20-May-24 | Private Sale (Planned) | 12,855 | $61.81 | $794,568.00 | (2%) 819.13K to 806.27K | |
| 17-May-24 6:05 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 17-May-24 | Sale (Planned) | 5,836 | $62.09 | $362,357.00 | (< 1%) 824.96K to 819.13K | |
| 17-May-24 6:01 PM View: | Tannenbaum Renee P Director | BioSante Pharmaceuticals, I... (ANIP) | 16-May-24 | Private Sale | 2,000 | $63.87 | $127,740.00 | (10%) 20.21K to 18.21K | |
| 17-May-24 6:05 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 16-May-24 | Sale (Planned) | 16,459 | $63.84 | $1,050,740.00 | (2%) 841.42K to 824.96K | |
| 17-May-24 6:05 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 15-May-24 | Private Sale (Planned) | 14,850 | $65.86 | $978,021.00 | (2%) 856.27K to 841.42K | |
| 16-May-24 5:02 PM View: | Lalwani Nikhil PRESIDENT & CEO Director | BioSante Pharmaceuticals, I... (ANIP) | 14-May-24 | Private Sale | 16,669 | $66.10 | $1,101,820.00 | (4%) 394.17K to 377.5K | |
| 13-May-24 5:25 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 13-May-24 | Private Sale (Planned) | 250 | $67.69 | $16,922.50 | (< 1%) 59.73K to 59.48K | |
| 03-May-24 5:48 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 01-May-24 | Private Sale (Planned) | 20,000 | $66.62 | $1,332,400.00 | (7%) 302.9K to 282.9K | |
| 22-Apr-24 6:26 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 19-Apr-24 | Sale (Planned) | 16,809 | $65.17 | $1,095,440.00 | (2%) 873.08K to 856.27K | |
| 22-Apr-24 6:26 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 18-Apr-24 | Private Sale (Planned) | 10,423 | $64.98 | $677,287.00 | (1%) 883.5K to 873.08K | |
| 17-Apr-24 4:33 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 17-Apr-24 | Sale (Planned) | 9,520 | $65.40 | $622,608.00 | (1%) 893.02K to 883.5K | |
| 17-Apr-24 4:33 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 16-Apr-24 | Sale (Planned) | 5,834 | $66.20 | $386,211.00 | (< 1%) 898.86K to 893.02K | |
| 17-Apr-24 4:33 PM View: | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS Director | BioSante Pharmaceuticals, I... (ANIP) | 15-Apr-24 | Private Sale (Planned) | 7,414 | $66.33 | $491,771.00 | (< 1%) 906.27K to 898.86K | |
| 15-Apr-24 6:28 PM View: | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | BioSante Pharmaceuticals, I... (ANIP) | 12-Apr-24 | Private Sale (Planned) | 250 | $67.79 | $16,947.50 | (< 1%) 59.98K to 59.73K | |
| 11-Apr-24 9:13 PM View: | Marken James G. SVP Ops & Prod Dev | BioSante Pharmaceuticals, I... (ANIP) | 10-Apr-24 | Payment of Exercise | 2,799 | $66.96 | $187,421.00 | (2%) 118.81K to 116.01K | |
| 11-Apr-24 9:12 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 10-Apr-24 | Payment of Exercise | 4,534 | $66.96 | $303,597.00 | (3%) 171.5K to 166.97K | |
| 02-Apr-24 6:59 PM View: | Gassert Chad SVP - CORP. DEV. & STRATEGY | BioSante Pharmaceuticals, I... (ANIP) | 01-Apr-24 | Private Sale (Planned) | 20,000 | $67.25 | $1,345,000.00 | (6%) 322.9K to 302.9K | |
| 25-Mar-24 4:17 PM View: | Carey Stephen P. SVP & CFO | BioSante Pharmaceuticals, I... (ANIP) | 23-Mar-24 | Payment of Exercise | 6,210 | $69.58 | $432,092.00 | (3%) 177.71K to 171.5K |
